'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

New research suggests that it could be possible to separate treatment from hallucinations when developing new drugs based on ...

New research has identified distinct neural circuits for the anti-anxiety and hallucinogenic effects of psychedelics.

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

with some evidence pointing to psychedelic mushrooms’ positive impact on some people with depression, anxiety and substance ...

Althea, a Boulder-based company, has created software they hope will become the de facto system for providers of ...

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental ...

Joe McKay tried everything medicine had to offer for the blinding headaches that began in the months after 9/11, when the ...